List of Tables
Table 1. Global Antiangiogenic Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Antiangiogenic Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Antiangiogenic Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Antiangiogenic Drugs Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Antiangiogenic Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Antiangiogenic Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Antiangiogenic Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Antiangiogenic Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Antiangiogenic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Antiangiogenic Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Antiangiogenic Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Antiangiogenic Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antiangiogenic Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Antiangiogenic Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antiangiogenic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Antiangiogenic Drugs Sales by Region (K Units), 2021–2026
Table 18. Global Antiangiogenic Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Antiangiogenic Drugs Sales by Region (K Units), 2027–2032
Table 20. Global Antiangiogenic Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Antiangiogenic Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Antiangiogenic Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Antiangiogenic Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Antiangiogenic Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Antiangiogenic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Antiangiogenic Drugs Sales by Country (K Units), 2021–2026
Table 27. North America Antiangiogenic Drugs Sales by Country (K Units), 2027–2032
Table 28. North America Antiangiogenic Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Antiangiogenic Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Antiangiogenic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Antiangiogenic Drugs Sales by Country (K Units), 2021–2026
Table 32. Europe Antiangiogenic Drugs Sales by Country (K Units), 2027–2032
Table 33. Europe Antiangiogenic Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Antiangiogenic Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Antiangiogenic Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Antiangiogenic Drugs Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Antiangiogenic Drugs Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Antiangiogenic Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Antiangiogenic Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Antiangiogenic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Antiangiogenic Drugs Sales by Country (K Units), 2021–2026
Table 42. Latin America Antiangiogenic Drugs Sales by Country (K Units), 2027–2032
Table 43. Latin America Antiangiogenic Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Antiangiogenic Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Antiangiogenic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Antiangiogenic Drugs Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Antiangiogenic Drugs Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Antiangiogenic Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Antiangiogenic Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Antiangiogenic Drugs Sales (K Units) by Type (2021–2026)
Table 51. Global Antiangiogenic Drugs Sales (K Units) by Type (2027–2032)
Table 52. Global Antiangiogenic Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Antiangiogenic Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Antiangiogenic Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Antiangiogenic Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Antiangiogenic Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Antiangiogenic Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Antiangiogenic Drugs Price (US$/Unit) by Type (2021–2026)
Table 59. Global Antiangiogenic Drugs Price (US$/Unit) by Type (2027–2032)
Table 60. Global Antiangiogenic Drugs Sales (K Units) by Application (2021–2026)
Table 61. Global Antiangiogenic Drugs Sales (K Units) by Application (2027–2032)
Table 62. Global Antiangiogenic Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Antiangiogenic Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Antiangiogenic Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Antiangiogenic Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Antiangiogenic Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Antiangiogenic Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Antiangiogenic Drugs Price (US$/Unit) by Application (2021–2026)
Table 69. Global Antiangiogenic Drugs Price (US$/Unit) by Application (2027–2032)
Table 70. Bayer Company Information
Table 71. Bayer Description and Business Overview
Table 72. Bayer Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Bayer Antiangiogenic Drugs Product
Table 74. Bayer Recent Developments/Updates
Table 75. Sanofi Company Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Sanofi Antiangiogenic Drugs Product
Table 79. Sanofi Recent Developments/Updates
Table 80. Eli Lilly Company Information
Table 81. Eli Lilly Description and Business Overview
Table 82. Eli Lilly Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Eli Lilly Antiangiogenic Drugs Product
Table 84. Eli Lilly Recent Developments/Updates
Table 85. Roche Company Information
Table 86. Roche Description and Business Overview
Table 87. Roche Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Roche Antiangiogenic Drugs Product
Table 89. Roche Recent Developments/Updates
Table 90. Pfizer Company Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Pfizer Antiangiogenic Drugs Product
Table 94. Pfizer Recent Developments/Updates
Table 95. Jiangsu Hengrui Pharmaceuticals Company Information
Table 96. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 97. Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product
Table 99. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 100. Chia Tai Tianqing Company Information
Table 101. Chia Tai Tianqing Description and Business Overview
Table 102. Chia Tai Tianqing Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Chia Tai Tianqing Antiangiogenic Drugs Product
Table 104. Chia Tai Tianqing Recent Developments/Updates
Table 105. Novartis Company Information
Table 106. Novartis Description and Business Overview
Table 107. Novartis Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Novartis Antiangiogenic Drugs Product
Table 109. Novartis Recent Developments/Updates
Table 110. AstraZeneca Company Information
Table 111. AstraZeneca Description and Business Overview
Table 112. AstraZeneca Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. AstraZeneca Antiangiogenic Drugs Product
Table 114. AstraZeneca Recent Developments/Updates
Table 115. Exelixis Company Information
Table 116. Exelixis Description and Business Overview
Table 117. Exelixis Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Exelixis Antiangiogenic Drugs Product
Table 119. Exelixis Recent Developments/Updates
Table 120. Boehringer Ingelheim Company Information
Table 121. Boehringer Ingelheim Description and Business Overview
Table 122. Boehringer Ingelheim Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Boehringer Ingelheim Antiangiogenic Drugs Product
Table 124. Boehringer Ingelheim Recent Developments/Updates
Table 125. Eisai Company Information
Table 126. Eisai Description and Business Overview
Table 127. Eisai Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Eisai Antiangiogenic Drugs Product
Table 129. Eisai Recent Developments/Updates
Table 130. Janssen Biotech Company Information
Table 131. Janssen Biotech Description and Business Overview
Table 132. Janssen Biotech Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Janssen Biotech Antiangiogenic Drugs Product
Table 134. Janssen Biotech Recent Developments/Updates
Table 135. Simcere Company Information
Table 136. Simcere Description and Business Overview
Table 137. Simcere Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Simcere Antiangiogenic Drugs Product
Table 139. Simcere Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Antiangiogenic Drugs Distributors List
Table 143. Antiangiogenic Drugs Customers List
Table 144. Antiangiogenic Drugs Market Trends
Table 145. Antiangiogenic Drugs Market Drivers
Table 146. Antiangiogenic Drugs Market Challenges
Table 147. Antiangiogenic Drugs Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report
List of Figures
Figure 1. Product Picture of Antiangiogenic Drugs
Figure 2. Global Antiangiogenic Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Antiangiogenic Drugs Market Share by Type: 2025 & 2032
Figure 4. Macromolecular Single-target Angiogenesis Inhibitor Product Picture
Figure 5. Small Molecule Multi-target Angiogenesis Inhibitor Product Picture
Figure 6. Endogenous Pan-target Angiogenesis Inhibitor Product Picture
Figure 7. Global Antiangiogenic Drugs Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Antiangiogenic Drugs Market Share by Application: 2025 & 2032
Figure 9. Cancer Therapy
Figure 10. Ophthalmic Diseases
Figure 11. Inflammatory and Autoimmune Diseases
Figure 12. Other
Figure 13. Global Antiangiogenic Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Antiangiogenic Drugs Market Size (US$ Million), 2021–2032
Figure 15. Global Antiangiogenic Drugs Sales (K Units), 2021–2032
Figure 16. Global Antiangiogenic Drugs Average Price (US$/Unit), 2021–2032
Figure 17. Antiangiogenic Drugs Report Years Considered
Figure 18. Antiangiogenic Drugs Sales Share by Manufacturers in 2025
Figure 19. Global Antiangiogenic Drugs Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Antiangiogenic Drugs Players: Market Share by Revenue in Antiangiogenic Drugs in 2025
Figure 21. Antiangiogenic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Antiangiogenic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Antiangiogenic Drugs Sales Market Share by Country (2021–2032)
Figure 24. North America Antiangiogenic Drugs Revenue Market Share by Country (2021–2032)
Figure 25. United States Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Antiangiogenic Drugs Sales Market Share by Country (2021–2032)
Figure 28. Europe Antiangiogenic Drugs Revenue Market Share by Country (2021–2032)
Figure 29. Germany Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Antiangiogenic Drugs Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Antiangiogenic Drugs Revenue Market Share by Region (2021–2032)
Figure 36. China Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Antiangiogenic Drugs Sales Market Share by Country (2021–2032)
Figure 44. Latin America Antiangiogenic Drugs Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Antiangiogenic Drugs Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Antiangiogenic Drugs Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Antiangiogenic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Antiangiogenic Drugs by Type (2021–2032)
Figure 55. Global Revenue Market Share of Antiangiogenic Drugs by Type (2021–2032)
Figure 56. Global Antiangiogenic Drugs Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Antiangiogenic Drugs by Application (2021–2032)
Figure 58. Global Revenue Market Share of Antiangiogenic Drugs by Application (2021–2032)
Figure 59. Global Antiangiogenic Drugs Price (US$/Unit) by Application (2021–2032)
Figure 60. Antiangiogenic Drugs Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
